Monday, May 4, 2015

In Central African Republic, Diamonds Fuel A Cycle of Violence and Poverty

The riches of the earth have been the boon and the bane of CAR for decades. Now they may also be leading to its disintegration.

BOMANDORO, Central African Republic — For the past two years, Guillaume Benam has spent most of his days doing back-breaking labor, hunting for the riches that so many of his countrymen have fought over for so long.

With three partners, he shovels heavy, wet clay soil into wooden sieves and baskets, then hunches in shin-deep water, sloshing the dirt and turning the stream the color of chocolate milk.

Then the three crouch and peer closely, cigarette smoke curling through stultifying jungle air, as Benam scrapes a trowel across a metal grate, looking for something the size of a pencil tip that could feed a family for a month or more: diamonds, some of the highest quality and most precious on earth.

So far, all he has to show for his labor are flecks, specks, grains and pebbles.

“It’s a gamble. Sometimes you get one, sometimes you get nothing,” Benam said. “We have been searching. I have been around for more than two years.”

Marcellin, 7, helps his father and another man dig at an artisanal mining site near Bomandoro, Central African Republic. Diggers must go down as much as 15 feet into the heavy clay layers of the forest looking for rough diamonds. Sept. 19, 2014 (VOA/Bagassi Koura)


Deep in the forests of one of the poorest countries on the planet, Benam’s quest for diamonds is a search for livelihood. It is also a symptom of the country’s woes, where the government’s absence has left a vacuum in the countryside, where sectarian and criminal bloodletting continues.

Central African Republic has become a nation whose borders exist only on maps, where governmental authority is limited mostly to the 25 square miles occupied by the capital, Bangui, if that.

Two years ago, mainly Muslim militias, known collectively as the Seleka, seized power, then plundered the country: from precious – diamonds, gold and ivory – to mundane – guns, cars, office supplies and food. A group of mainly Christian and animist militias later retaliated, and drove the Seleka into the countryside.

Concentration of Diamond Mines in the Central African Republic

This map shows the general distribution of ‘artisanal’ diamond mines in the Central African Republic. Data courtesy IPIS and United Nations panel of experts on the Central African Republic.


Today, CAR is less a country than a collection of fiefdoms, ruled by gang-like armed groups, where religious, military, political and ethnic factions struggle for anything that might yield revenue.

It’s a state “that has long ceased to exist,” the International Crisis Group said in a report earlier this year.

In a nation roiled by ethnic animosity, undercurrents of religious tension and a history of bad government, this latest struggle for the country’s natural wealth was by all accounts inevitable.

If it wasn’t diamonds, it would likely be something else.

Diggers must go down as much as 15 feet into the heavy clay layers of forest looking for rough diamonds. Many labor for weeks or months without finding anything larger than a pencil eraser. Sept. 19, 2014 (VOA/Bagassi Koura)

The Curse of Plenty


Travel anywhere across Central African Republic’s jungles, forest, river valleys and arid plains, where vast natural riches lie, and you begin to grasp the contradictions of how a country so wealthy can be so poor.

Under French colonial rule, foreign companies exploited the country’s diamonds, gold, cotton, timber, rubber and other natural resources, but left little in the way of long-term infrastructure or governance that might knit the country into a durable whole.

The country gained independence in 1960 but, as is often the case, newfound wealth and a weak government fueled a surge in corruption and a struggle to control the bounty of gems and other resources.

A man who gave his name as Sylvain said he was in charge of the anti-balaka militia in the region around Boda. Armed mainly with machetes, the militia groups now control the rich diamond mining areas in the southwest part of CAR. Sept. 18, 2004 (VOA/Bagassi Koura)


A 1965 coup by former army colonel Jean-Bedel Bokassa set a pattern of instability for the next 49 years, creating “a political culture characterized by violence and economic predation,” according to the United Nations.

During his 14 years in power, Bokassa ruled with an iron fist. He proclaimed himself emperor in 1977. The opulent coronation he staged, modeled on Napoleon’s, cost tens of millions of dollars, an astronomical sum for such an impoverished country.

Two years after the coronation, food riots, and a scandal involving schoolchildren, school uniforms and dozens of deaths resulted in French troops ousting Bokassa. The following 24 years were marked by a military junta, mutinies, coups and disputed elections.

In 2003, General Francois Bozize seized power. Despite a low-level insurgency and a diamond-related dispute in 2008 that stoked resentment, Bozize held on until March 2013, when a group of militias and rebel groups known as the Seleka emerged out of traditional Muslim strongholds in the north and east and seized Bangui.

The United Nations estimates around 3,000 civilians were killed between last December and mid-August. Foreign media and nongovernmental groups estimate the death toll exceeded 5,000.

Muslims are a minority in Central African Republic– only around 15 percent of the country’s 4.6 million inhabitants.

For many Muslims, the rise of the Seleka was a remedy for past injustices at the hands of the Christian majority. In the north and east, infrastructure like roads or electricity is rudimentary at best, and income lags considerably from that of the west and southwest.

Motorists drive through the center of the CAR capital Bangui on Sept. 22, 2014. The city has continued to be racked by violence since anti-balaka forces drove out Seleka militia December 2013. (VOA/Bagassi Koura)


The 10 months of Seleka rule, under Michel Djotodia, were characterized by fear and pillage, from the countryside to Bangui.

“Throughout the period in which the Seleka controlled the capital, looting of houses, shops and medical centers reached endemic levels,” said IPIS, a Belgian research firm, in a report released November 24. “In their advance through the central and western parts of the country, Seleka forces again systematically plundered villages and towns, sometimes even razing entire villages to the ground.”

For many Christians, the rise of the Seleka confirmed their fears that Muslims were out to cement control over key parts of the economy, like the diamond trade.

Adding to the chaos were shifting allegiances among the ethnic groups making up the two sides, and the involvement of mercenaries and irregular units from Chad, Sudan and elsewhere, specifically allied with Seleka groups.

The Seleka reign ended in December 2013 with the counterattack of mainly Christian militias known as the anti-balaka, which literally means “anti-machete,” a reference to the weapon commonly wielded by the Seleka fighters.

Seleka groups retreated from the capital into the countryside. But they retained swaths of territory in the country’s north and center.

Men shop at a kiosk in Bangui's Kilometer 5, a mainly Muslim neighborhood within the capital. The city has been sharply divided between Christians and Muslims since the anti-balaka militia took control last December from the Seleka groups. Sept. 5, 2014 (VOA/Bagassi Koura)


Djotodia followed Bozize into exile in Benin. The mayor of Bangui, a stylish 58-year-old insurance broker named Catherine Samba-Panza, was appointed interim president in January.

In August, in a conciliatory gesture to Seleka groups, she appointed a Muslim as prime minister: Mahamat Kamoun. The Seleka nonetheless derided his appointment.

The country is now essentially cut in two.



Three men look out at passersby at the compound of the mayor of Boda, in the heart of the enclave where thousands of Muslims are virtually trapped by anti-balaka militia. Tensions between Christians and Muslims have turned outright violent since the Seleka took over Bangui in 2013 and anti-balaka militia reclaimed it. Sept. 19, 2014 (VOA/Bagassi Koura)

Muslim men sit near the mayor's house in the provincial town of Boda, Central African Republic, where some 1,400 Muslim men, women and children are trapped by anti-balaka militia. Relations between the country’s Christians and Muslims, long uneasy, have turned outright poisonous since the brief period of Seleka rule in 2013. Sept. 19, 2014 (VOA/Bagassi Koura)

Diamond City in Ruins


In their sweep to power, anti-balaka groups were eager to exact revenge on Seleka fighters, and Muslims more broadly, but also to reclaim anything of any value — diamonds foremost.

Muslims were targeted throughout the country. The town of Boda, near where Benam and his partners have spent countless hours in mud and water looking for gems, was no exception.

Located about a five-hour car ride west of Bangui, the town, known as Boda la Belle, or Boda the Beautiful, saw interreligious violence following the Seleka’s sudden late-January departure.

Houses were destroyed, shops looted, a mosque ravaged. More than a hundred people were killed, mostly Muslims, officials said.

“We decided to become [anti-balaka] because Muslims rallied to the Seleka who armed them,” said a man who gave his name as Sylvain and who said he was chief of the anti-balaka in the Boda region. “And one day they started shooting at Christians to kill. This is what we revolted against. We first fled into the bush and then we said we cannot leave the country. And we’ve come back to defend.”

Altahir Abdallah, an elder within Boda's Muslim community, said Muslims are killed on a near daily basis by anti-balaka militiamen. The city's Muslim population has either fled or has taken refuge in an enclave within Boda. Sept. 19, 2014 (VOA/Bagassi Koura)

A city of 30,000 people, where dirt roads, muddy puddles and high fences separate the wealthy few from the masses, Boda now has a new line of separation: an enclave, a wall-less ghetto where some 1,400 Muslims who have remained are now trapped, guarded by anti-balaka fighters.

“We cannot move,” Altahir Abdallah, 67, an elder within Boda’s Muslim community, told VOA in an interview in September. “Even this little bridge that you see, we cannot pass over, no Muslim can cross. You move away from the enclave and you are killed.”

In this region, the owners of diamond mines – open pit, small-scale digs known as “artisanal” operations – were all Muslims until late January.

Mahamat Adamou, 70, who works as a middleman between miners and a Bangui buying house, said he was afraid to leave the enclave.

“When the [attack] began, they picked up all my mine workings: all the tools, pumps, diamonds. Christians have taken it all up,” he told VOA. “And they have taken over diamond mining on my sites.”

Bomandoro, the cluster of mines and pits where Benam and his partners are digging, is an hour’s ride away from Boda by motorbike, over roads losing ground to the encroaching forest.

The area is renowned among diggers, who have dubbed it “lango ousse,” which translates from the Sango language as “two days” – as in, it takes only two days to find something worthwhile.

Mahamat Adamou, 70, of Boda, who works as a middleman between miners and a Bangui buying house, said he was afraid to leave his cloistered enclave, guarded closely by anti-balaka militiamen. Sept. 19, 2014. (VOA/Bagassi Koura)

Anti-balaka fighters monitor road traffic and miners’ activity. Benam and his partners, for the most part, have been left alone.

“We do not know anything about the mines,” Adamou said. “We only know that they [dig for] diamonds. We do not know where [they] lead.”

In 2012, Central African Republic ranked 12th among diamond producers in the world, according to the Kimberley Process, a multinational organization comprised of diamond-producing states, traders and civil society groups seeking to prevent the gems from fueling wars or insurgencies.

CAR is not alone in this part of the world either: Most of its neighbors produce far greater volumes.

What makes CAR unusual is the quality of its gemstones, prized not for industrial uses, like diamond-tipped, tunnel-cutting machines, but for use in jewelry and watches.

Experts rank its diamond quality among the top five in the world. The country exported 378,000 carats of diamond in 2012, worth around $167.05 per carat, about $63 million.

By comparison, its neighbor, the Democratic Republic of Congo, exported 19.5 million carats that same year, but they were worth only $13.41 per carat.

Anti-balaka militia in Boda are made up of young boys and older men, who oversee artisanal diamond mines, gold digging and other resource extraction in the region. Sept. 18, 2014 (VOA/Bagassi Koura)

Children play in the puddles within the Muslim enclave in Boda, where up to 1,400 Muslim men, women and children are living, guarded over by anti-balaka militias. Boda lies in the heart of the diamond-rich area of southwestern Central Africa Republic. Sept. 19, 2014 (VOA/Bagassi Koura)


For Seleka militias, control of diamond production was a key grievance against Bozize, who in 2008 sought to create a monopoly over the domestic market for his relatives and members of his ethnic group, according to the International Crisis Group, a Belgian-based think-tank.

In May 2013, as the Seleka took control of Bangui, Kimberley Process regulators banned CAR diamonds from world markets, an attempt to keep the gems from fueling further violence.

Camille Guimale, a veteran diamond cutter, polisher and appraiser in Bangui, said his work has nearly dried up in the past three years, because of the conflict. The official trade nationwide has ground to a halt, but local and international experts say smuggling and illegal exports are flourishing, helping armed groups building up arsenals and assets. Sept. 22, 2014 (VOA/Bagassi Koura)

But illegal export networks proliferated, as many of the Muslim buyers fled to neighboring countries such as Cameroon and continued overseeing export routes.

In November, the United Nations estimated that 140,000 carats of diamonds, worth $24 million, have been exported illegally since the ban took effect. That includes a shipment of 6,634 carats from CAR that was seized in Antwerp in the Belgian offices of Badica, the CAR diamond marketing company.

According to a former CAR mines minister, Olivier Mailbangar, up to 80 percent of the country’s diamonds are exported fraudulently.

Still, the ban has had an impact, experts said, crimping cash flow for diamond-buying offices, cutting capital investment for heavy machinery and mechanized tools, and pushing down production in some areas. As a result, per-carat prices have declined as official buyers build up inventories and wait out the ban.

At the same time, one of the main conduits for smuggled diamonds, Cameroon, whose gems are close in quality to CAR’s, has officially reported a drop in exports, well below estimated production. That, according to IPIS, “implies that Central African diamonds easily find their way into the parallel market through Cameroon,” harming its legal diamond industry.

At a Kimberley Process plenary meeting in Guangzhou, China, in November, delegates rejected a request by CAR to partially lift the ban, a decision they said they would revisit before the group’s next meeting in June.

“It’s a balancing act. There are people who are arguing that by keeping the ban in place, you are encouraging smuggling and destroying a sector that was fragile to begin with,” said Bady Baldé, regional director for the Extractive Industries Transparency Initiative, a Norway-based coalition trying to improve how countries exploit natural resources.

Terah DeJong, a Cote d’Ivoire-based expert who runs a U.S.- and European Union-funded project trying to improve the diamond trade, said it’s possible Kimberley Process officials will allow partial exports from the mines in western CAR. Those are mainly controlled by the Christian and animist militias. That could help refill government coffers, but it would likely stoke resentment among Muslim-controlled mining areas.

“There are many technical and political concerns with such an approach,” DeJong, who attended the Guangzhou meeting, said in an email interview. “How to ensure that it doesn’t fuel conflict by allowing western [anti-balaka] diamonds to get KP certificates but not eastern [ex-Seleka] diamonds to do so? How to ensure that eastern diamonds do not simply get smuggled into the west?”

Joseph Agbo, who heads the country’s Ministry of Mines and Geology, said that the diamond industry normally accounts for 51 percent of the country’s export earnings. Now the government no longer has any control over the industry, he said. Government efforts to restore authority outside of Bangui have failed. Seleka-linked groups attacked government officials across the country recently as they sought to resume their posts.

Agbo echoed the argument that many government officials and official diamond exporters now make: The embargo facilitates fraud and undermines efforts to rebuild a functioning government.

“The more the [ban] persists, the more vultures are in the process to set up in CAR to divert our resources,” said Vianney Koyandakpa, a Bangui-based diamond exporter.

Police officers from Burundi patrol the streets of Bangui, part of a multinational peacekeeping force helping to restore calm to the Central African Republic. But with the exception of French forces, most of the international units are widely seen as ineffectual. (VOA/Bagassi Koura)

Soldiers from the Democratic Republic of Congo salute during a ceremony honoring them for their participation with an African Union peacekeeping mission in Central African Republic. Sept. 13, 2014 (VOA/Bagassi Koura)

To Be or Not to Be

The question whether CAR will continue to exist as anything more than lines on a map may hinge largely on the demands of its neighbors, on its colonial ruler and on the uneven attentions of the international community.

“CAR has arguably never really been a state, even since independence, in terms of its reach and access and control,” DeJong said. “So you have to ask the question: Are you looking something new, or just is a continuation of what’s been going on for years?”

The capital Bangui has seen sporadic violence since the Seleka militia were driven out, and the city's Muslim and Christian neighborhoods are largely separated from one another. The city remains the economic hub of the country. Sept. 16, 2014 (VOA/Bagassi Koura)

In September, the United Nations deployed a 7,500-person peacekeeping force, including African troops, international police officers and other soldiers and officers.

France, which helped depose Bokassa in 1979, has continued to play an active role, with 2,000 soldiers deployed since last December. French troops on patrol outside the capital have been attacked regularly, and have called in air support from French fighter jets based in Chad on at least one occasion. France has also supported CAR’s call for a partial lifting of the diamond ban, to help the government refill its coffers.

CAR’s neighbors take an equally active role.

Cameroon hosts many of the Muslim diamond traders who fled the anti-balaka onslaught, and is the conduit for much of CAR’s gold, as well. Chad, fearing instability along a porous border, has allowed mercenaries to serve as security guards for Bozize, provided support for Seleka groups as they took Bangui, and carved out a buffer zone in northern CAR. Sudan, too, was widely reported to be a major conduit for arms supplies, equipment for the Seleka.

A man who refused to give his name digs at a site near Bomandoro, Central African Republic, looking for diamonds. The area is known as 'two days' in the local Sango language, referring to the amount of time it takes a miner to find a diamond in the region. Sept. 19, 2014 (VOA/Bagassi Koura)

Moreover, with local commanders and militia leaders eager to fund their operations, having reliable export partners, or smugglers, is essential, meaning deeper ties with Sudanese, Chadian, Congolese and Cameroonian business interests.

This is true, experts said, for both anti-balaka and Seleka, some of whose leaders have called for breaking up the country. The more militia leaders can build up their revenue streams – through diamond smuggling, gold exports, ivory poaching, highway taxes, extortion – the more they will be able to resist the central government. That in turn will make it harder to find a lasting political solution.

Maxime Kazagui, the CAR government representative to the Kimberley Process negotiations, told VOA that for all the allure of diamonds, they have yielded nothing close to what they should have for his country:

“In truth, diamonds have made us more unhappy than happy.”




About This Report

Written and Reported by Bagassi Koura and Mike Eckel

Bagassi Koura, a veteran broadcast reporter with VOA’s French-to-Africa Service, has reported from Central African Republic twice over the past year, covering the aftermath of the Seleka reign and the efforts to restore peace. A native of Burkina Faso, Koura has reported from around Africa, including Kenya, Cote D’Ivoire and Mali. Prior to coming to VOA in 2005, Koura worked as a freelancer for Reuters TV, AFP and The Panos Institute of West Africa.

Credits:
Created and Produced by Mike Eckel

Photos explain you about world


Photos are taking you around the world with Plus & Minus

A look at the best news photos from around the world.


1

Pedestrians pass before Storm Troopers at a toy shop in Tokyo.
May 4th is called the "Star Wars Day" among Star Wars fans
as the famous phrase "May the Force be with you" in the movie
sounds like "May the 4th be with you."


2

A young Indian Buddhist monk opens the petals of a lotus
flower as he sits with others while offering prayers on the
occasion of Buddha Purnima in Bangalore, during the 2559th
Buddha Jayanthi or birth celebrations of Buddha.


3

Men duck for cover as shots are fired in Bujumbura, Burundi.


4

A competitor goes down steps of an alley during the Favelas
Mountain Bike circuit at Turano shantytown in Rio de Janeiro,
Brazil, May 3, 2015.


5

Nepalese Buddhists light incense sticks at the Boudhanath
Stupa during Buddha Jayanti, or Buddha Purnima, festival
in Kathmandu.


6

Israeli security forces scuffle with a demonstrater during a
protest called by members of the Ethiopian community
against alleged police brutality and institutionalized
discrimination in Tel Aviv, May 03, 2015.


7

A group of 1000 customers receive a facial massage at
a sports center in Jinan, Shandong province, China.

8

A member of Afghan security force inspects the site of
a suicide attack in Kabul.


9

Wax statues at the Workhouse Prison Museum in Lorton,
Virginia, show the 1917 force-feeding of Lucy Burns,
an American suffragist and women's rights advocate
who was on a hunger strike. (Photo by Diaa Bekheet)



10
A Chinese girl looks up while playing in a bed of blooming
flowers at the Fragrant Hills Park in suburban Beijing.



11

A woman walks along the rows of small stone statues of "jizo"
representing the unborn children at Zojoji Buddhist temple
in Tokyo. Jizo, which is one of the most beloved figures of
Japanese Buddhism, are believed to protect deceased children.



12
A worker of the recently closed Swan garments factory covers
 her face with a scarf to shelter herself from the sun as she
participates in a protest outside the Bangladesh Garment
Manufacturers and Export Association (BGMEA) office
in Dhaka.

Photos explain you about world


Photos are taking you around the world with Plus & Minus

A look at the best news photos from around the world.


1

Pedestrians pass before Storm Troopers at a toy shop in Tokyo.
May 4th is called the "Star Wars Day" among Star Wars fans
as the famous phrase "May the Force be with you" in the movie
sounds like "May the 4th be with you."


2

A young Indian Buddhist monk opens the petals of a lotus
flower as he sits with others while offering prayers on the
occasion of Buddha Purnima in Bangalore, during the 2559th
Buddha Jayanthi or birth celebrations of Buddha.


3

Men duck for cover as shots are fired in Bujumbura, Burundi.


4

A competitor goes down steps of an alley during the Favelas
Mountain Bike circuit at Turano shantytown in Rio de Janeiro,
Brazil, May 3, 2015.


5

Nepalese Buddhists light incense sticks at the Boudhanath
Stupa during Buddha Jayanti, or Buddha Purnima, festival
in Kathmandu.


6

Israeli security forces scuffle with a demonstrater during a
protest called by members of the Ethiopian community
against alleged police brutality and institutionalized
discrimination in Tel Aviv, May 03, 2015.


7

A group of 1000 customers receive a facial massage at
a sports center in Jinan, Shandong province, China.

8

A member of Afghan security force inspects the site of
a suicide attack in Kabul.


9

Wax statues at the Workhouse Prison Museum in Lorton,
Virginia, show the 1917 force-feeding of Lucy Burns,
an American suffragist and women's rights advocate
who was on a hunger strike. (Photo by Diaa Bekheet)



10
A Chinese girl looks up while playing in a bed of blooming
flowers at the Fragrant Hills Park in suburban Beijing.



11

A woman walks along the rows of small stone statues of "jizo"
representing the unborn children at Zojoji Buddhist temple
in Tokyo. Jizo, which is one of the most beloved figures of
Japanese Buddhism, are believed to protect deceased children.



12
A worker of the recently closed Swan garments factory covers
 her face with a scarf to shelter herself from the sun as she
participates in a protest outside the Bangladesh Garment
Manufacturers and Export Association (BGMEA) office
in Dhaka.

Study Links HIV to Eye Disease



Ethiopian ophthalmologist Dr. Tilahun Kiros examines a patient's eyes at the Quiha Eye Hospital Vision Center in Mekelle, Ethiopia.

A new study adds to growing evidence that HIV infected people have immune systems similar to those who are much older. This occurs even when they are being treated with antiretroviral drugs. The older-acting immune systems can make them more susceptible to certain diseases.

Dr. Douglas Jabs said while HIV/AIDS patients are living longer than ever – thanks to antiretroviral drugs – they are at greater risk of developing age-related diseases. These include cardiovascular disease, cancer, diabetes and even frailty.

Jabs is lead author of a new study that says they are also more susceptible to age-related macular degeneration or AMD. The disease can cause vision loss and blindness in its late stages. AMD is listed as the “leading cause of visual impairment and blindness in people over 65.” It causes damage to part of the retina called the macula, which is responsible for clear, sharp vision.

Jabs is a professor of both ophthalmology and medicine at the Icahn School of Medicine at Mount Sinai in New York.

He said, “There is an emerging body of data in the HIV literature that patients with HIV infection, who are treated with antiretroviral therapy and have immune recovery – so now they’re not getting opportunistic infections – they have markedly improved survivals – they all have a shortened survival relative to patients who are not HIV infected when you age match them.”

They appear to have – what’s called – accentuated or possibly accelerated aging.

“In addition, the immunologists are showing that the immune system of patients with HIV, who are treated with antiretroviral therapy and immune recovered, have changes similar to the immune systems of 75 year olds called immunosenescence,” he said.

Dr. Jabs and his colleagues studied more than 1,800 HIV patients between the ages of 13 and 73 from 1998 to 2011. The study says their immune systems were always activated and they had chronic inflammation – a condition that’s been linked to a number of health problems. In a sense, their immune systems had a lot of wear and tear.

“They’ve had a lot of immune stimulation. They’ve got a lot of cells that are responding to the things that they’ve seen. But they’re losing some of the ability to respond to new challenges. When with the immune activation they have systemic levels of inflammation using simple biomarkers. Those pieces of information suggested that because of the accelerated aging and because of the issues related to inflammation and immunosenescence that maybe patients who are HIV infected would have similar age-related changes in the eye. And so we decided to look for AMD,” he said.

When compared to a group of people of similar ages not infected with the AIDS virus they had a fourfold greater prevalence of macular degeneration.

‘We looked at all the different drugs they’re taking. It’s not related to the drugs. It’s not due to the drugs at all. It’s due to the beating the immune system has taken dealing with HIV and everything else. And it’s similar by the way to what the immune system looks like in a 75 year old adult, except these people are all 45,” he said.

The next step, said Dr. Jabs, is to try to understand what’s going on – to determine whether chronic activation of the immune system and systemic inflammation are actually the reasons for greater risk of AMD. In the meantime, he said the message is one of vigilance – manage diseases in HIV patents the way they would be treated in older individuals.

Study Links HIV to Eye Disease



Ethiopian ophthalmologist Dr. Tilahun Kiros examines a patient's eyes at the Quiha Eye Hospital Vision Center in Mekelle, Ethiopia.

A new study adds to growing evidence that HIV infected people have immune systems similar to those who are much older. This occurs even when they are being treated with antiretroviral drugs. The older-acting immune systems can make them more susceptible to certain diseases.

Dr. Douglas Jabs said while HIV/AIDS patients are living longer than ever – thanks to antiretroviral drugs – they are at greater risk of developing age-related diseases. These include cardiovascular disease, cancer, diabetes and even frailty.

Jabs is lead author of a new study that says they are also more susceptible to age-related macular degeneration or AMD. The disease can cause vision loss and blindness in its late stages. AMD is listed as the “leading cause of visual impairment and blindness in people over 65.” It causes damage to part of the retina called the macula, which is responsible for clear, sharp vision.

Jabs is a professor of both ophthalmology and medicine at the Icahn School of Medicine at Mount Sinai in New York.

He said, “There is an emerging body of data in the HIV literature that patients with HIV infection, who are treated with antiretroviral therapy and have immune recovery – so now they’re not getting opportunistic infections – they have markedly improved survivals – they all have a shortened survival relative to patients who are not HIV infected when you age match them.”

They appear to have – what’s called – accentuated or possibly accelerated aging.

“In addition, the immunologists are showing that the immune system of patients with HIV, who are treated with antiretroviral therapy and immune recovered, have changes similar to the immune systems of 75 year olds called immunosenescence,” he said.

Dr. Jabs and his colleagues studied more than 1,800 HIV patients between the ages of 13 and 73 from 1998 to 2011. The study says their immune systems were always activated and they had chronic inflammation – a condition that’s been linked to a number of health problems. In a sense, their immune systems had a lot of wear and tear.

“They’ve had a lot of immune stimulation. They’ve got a lot of cells that are responding to the things that they’ve seen. But they’re losing some of the ability to respond to new challenges. When with the immune activation they have systemic levels of inflammation using simple biomarkers. Those pieces of information suggested that because of the accelerated aging and because of the issues related to inflammation and immunosenescence that maybe patients who are HIV infected would have similar age-related changes in the eye. And so we decided to look for AMD,” he said.

When compared to a group of people of similar ages not infected with the AIDS virus they had a fourfold greater prevalence of macular degeneration.

‘We looked at all the different drugs they’re taking. It’s not related to the drugs. It’s not due to the drugs at all. It’s due to the beating the immune system has taken dealing with HIV and everything else. And it’s similar by the way to what the immune system looks like in a 75 year old adult, except these people are all 45,” he said.

The next step, said Dr. Jabs, is to try to understand what’s going on – to determine whether chronic activation of the immune system and systemic inflammation are actually the reasons for greater risk of AMD. In the meantime, he said the message is one of vigilance – manage diseases in HIV patents the way they would be treated in older individuals.

Thousands of Students Around the World Participate in Inaugural TOEFL® Young Students Series GO English! Project

Thousands of Students Around the World Participate in Inaugural TOEFL® Young Students Series GO English! Project

Thousands of Students Around the World Participate in Inaugural TOEFL® Young Students Series GO English! Project

Thousands of Students Around the World Participate in Inaugural TOEFL® Young Students Series GO English! Project

MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets

MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets

MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets

MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets

Securiport Announces Innovative Solutions as an INTERPOL World Strategic Partner at the Inaugural INTERPOL World 2015 Biennial Conference

Securiport Announces Innovative Solutions as an INTERPOL World Strategic Partner at the Inaugural INTERPOL World 2015 Biennial Conference

Securiport Announces Innovative Solutions as an INTERPOL World Strategic Partner at the Inaugural INTERPOL World 2015 Biennial Conference

Securiport Announces Innovative Solutions as an INTERPOL World Strategic Partner at the Inaugural INTERPOL World 2015 Biennial Conference

Samsung Outlines Approach for Smart Lighting at LIGHTFAIR International 2015

Samsung Outlines Approach for Smart Lighting at LIGHTFAIR International 2015

Samsung Outlines Approach for Smart Lighting at LIGHTFAIR International 2015

Samsung Outlines Approach for Smart Lighting at LIGHTFAIR International 2015

Sunday, May 3, 2015

10 sea Creatures You Won't Believe Exist

https://www.youtube.com/watch?v=pGBNLxPMhhI

some times we believe things by naked eyes. But some times we do not accept without evidence.

10 sea Creatures You Won't Believe Exist

https://www.youtube.com/watch?v=pGBNLxPMhhI

some times we believe things by naked eyes. But some times we do not accept without evidence.

15 Things You Didn't Know About Earth

https://www.youtube.com/watch?v=u9A_HSO1TnA

It is nature. man then tries to change it every minute, but finally nature wins over man.

15 Things You Didn't Know About Earth

https://www.youtube.com/watch?v=u9A_HSO1TnA

It is nature. man then tries to change it every minute, but finally nature wins over man.

Planet Earth 100 Million Years In The Future - What will happen to our world?

https://www.youtube.com/watch?v=uQ91AxUqHck&sns=tw

watch carefully and think about the ways that we follow to save world to be lived long long years.
give a contribution by your activities make the world to be lived long days healthy.

Planet Earth 100 Million Years In The Future - What will happen to our world?

https://www.youtube.com/watch?v=uQ91AxUqHck&sns=tw

watch carefully and think about the ways that we follow to save world to be lived long long years.
give a contribution by your activities make the world to be lived long days healthy.

Saturday, May 2, 2015

Fun fun fun...........100% dont miss;;;; dont try it own

https://www.facebook.com/Rmbds/videos/1132406770111257/?pnref=story

Fun fun fun...........100% dont miss;;;; dont try it own

https://www.facebook.com/Rmbds/videos/1132406770111257/?pnref=story

Drugs that activate brain stem cells may reverse multiple sclerosis

NIH-funded study identifies over-the-counter compounds that may replace damaged cells

Two drugs already on the market — an antifungal and a steroid — may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. The study was partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.



An artist’s representation of the study. Scientists found that certain drugs were able to promote remyelination in mouse models of multiple sclerosis. Image courtesy of Case Western Reserve University; Illustrator: Megan Kern

Specialized cells called oligodendrocytes lay down multiple layers of a fatty white substance known as myelin around axons, the long “wires” that connect brain cells. Myelin acts as an insulator and enables fast communication between brain cells. In multiple sclerosis there is breakdown of myelin and this deterioration leads to muscle weakness, numbness and problems with vision, coordination and balance.

“To replace damaged cells, the scientific field has focused on direct transplantation of stem cell-derived tissues for regenerative medicine, and that approach is likely to provide enormous benefit down the road. We asked if we could find a faster and less invasive approach by using drugs to activate native nervous system stem cells and direct them to form new myelin. Our ultimate goal was to enhance the body’s ability to repair itself,” said Paul J. Tesar, Ph.D., associate professor at Case Western Reserve School of Medicine in Cleveland, and senior author of the study.

It is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder. Current therapies for multiple sclerosis include anti-inflammatory drugs, which help prevent the episodic relapses common in multiple sclerosis, but are less effective at preventing long-term disability. Scientists believe that therapies that promote myelin repair might improve neurologic disability in people with multiple sclerosis. 

Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells. OPCs are found to multiply in the brains of multiple sclerosis patients as if to respond to myelin damage, but for unknown reasons they are not effective in restoring white matter. In the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination. 

OPCs have been difficult to isolate and study, but Dr. Tesar and his colleagues, in collaboration with Robert Miller, Ph.D., professor at George Washington University School of Medicine and Health Sciences in Washington, D.C., developed a novel method to investigate these cells in a petri dish. Using this technique, they were able to quickly test the effects of hundreds of drugs on the stem cells.

The compounds screened in this study were obtained from a drug library maintained by NIH’s National Center for Advancing Translational Sciences (NCATS). All are approved for use in humans. NCATS and Dr. Tesar have an ongoing collaboration and plan to expand the library of drugs screened against OPCs in the near future to identify other promising compounds.

Dr. Tesar’s team found that two compounds in particular, miconazole (an antifungal) and clobetasol (a steroid), stimulated mouse and human OPCs into generating myelin-producing cells.

Next, they examined whether the drugs, when injected into a mouse model of multiple sclerosis, could improve re-myelination. They found that both drugs were effective in activating OPCs to enhance myelination and reverse paralysis. As a result, almost all of the animals regained the use of their hind limbs. They also found that the drugs acted through two very different molecular mechanisms. 

“The ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,” said Ursula Utz, Ph.D., program director at the NINDS.

Dr. Tesar and his colleagues caution that more research is needed before miconazole and clobetasol can be tested in multiple sclerosis clinical trials. They are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.

“Off-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms. We are working tirelessly to ready a safe and effective drug for clinical use,” Dr. Tesar said.

This work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.

The NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

The National Center for Advancing Translational Sciences is a distinctly different entity in the research ecosystem. Rather than targeting a particular disease or fundamental science, NCATS focuses on what is common across diseases and the translational process. The Center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate advancements in translational science that bring about tangible improvements in human health. For more information, visit http://www.ncats.nih.gov.

Drugs that activate brain stem cells may reverse multiple sclerosis

NIH-funded study identifies over-the-counter compounds that may replace damaged cells

Two drugs already on the market — an antifungal and a steroid — may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. The study was partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.



An artist’s representation of the study. Scientists found that certain drugs were able to promote remyelination in mouse models of multiple sclerosis. Image courtesy of Case Western Reserve University; Illustrator: Megan Kern

Specialized cells called oligodendrocytes lay down multiple layers of a fatty white substance known as myelin around axons, the long “wires” that connect brain cells. Myelin acts as an insulator and enables fast communication between brain cells. In multiple sclerosis there is breakdown of myelin and this deterioration leads to muscle weakness, numbness and problems with vision, coordination and balance.

“To replace damaged cells, the scientific field has focused on direct transplantation of stem cell-derived tissues for regenerative medicine, and that approach is likely to provide enormous benefit down the road. We asked if we could find a faster and less invasive approach by using drugs to activate native nervous system stem cells and direct them to form new myelin. Our ultimate goal was to enhance the body’s ability to repair itself,” said Paul J. Tesar, Ph.D., associate professor at Case Western Reserve School of Medicine in Cleveland, and senior author of the study.

It is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder. Current therapies for multiple sclerosis include anti-inflammatory drugs, which help prevent the episodic relapses common in multiple sclerosis, but are less effective at preventing long-term disability. Scientists believe that therapies that promote myelin repair might improve neurologic disability in people with multiple sclerosis. 

Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells. OPCs are found to multiply in the brains of multiple sclerosis patients as if to respond to myelin damage, but for unknown reasons they are not effective in restoring white matter. In the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination. 

OPCs have been difficult to isolate and study, but Dr. Tesar and his colleagues, in collaboration with Robert Miller, Ph.D., professor at George Washington University School of Medicine and Health Sciences in Washington, D.C., developed a novel method to investigate these cells in a petri dish. Using this technique, they were able to quickly test the effects of hundreds of drugs on the stem cells.

The compounds screened in this study were obtained from a drug library maintained by NIH’s National Center for Advancing Translational Sciences (NCATS). All are approved for use in humans. NCATS and Dr. Tesar have an ongoing collaboration and plan to expand the library of drugs screened against OPCs in the near future to identify other promising compounds.

Dr. Tesar’s team found that two compounds in particular, miconazole (an antifungal) and clobetasol (a steroid), stimulated mouse and human OPCs into generating myelin-producing cells.

Next, they examined whether the drugs, when injected into a mouse model of multiple sclerosis, could improve re-myelination. They found that both drugs were effective in activating OPCs to enhance myelination and reverse paralysis. As a result, almost all of the animals regained the use of their hind limbs. They also found that the drugs acted through two very different molecular mechanisms. 

“The ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,” said Ursula Utz, Ph.D., program director at the NINDS.

Dr. Tesar and his colleagues caution that more research is needed before miconazole and clobetasol can be tested in multiple sclerosis clinical trials. They are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.

“Off-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms. We are working tirelessly to ready a safe and effective drug for clinical use,” Dr. Tesar said.

This work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.

The NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

The National Center for Advancing Translational Sciences is a distinctly different entity in the research ecosystem. Rather than targeting a particular disease or fundamental science, NCATS focuses on what is common across diseases and the translational process. The Center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate advancements in translational science that bring about tangible improvements in human health. For more information, visit http://www.ncats.nih.gov.

How to identify drugs that work best for each patient

Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy.

More than 100 drugs have been approved to treat cancer, but predicting which ones will help a particular patient is an inexact science at best.

A new device developed at MIT may change that. The implantable device, about the size of the grain of rice, can carry small doses of up to 30 different drugs. After implanting it in a tumor and letting the drugs diffuse into the tissue, researchers can measure how effectively each one kills the patient’s cancer cells.

Such a device could eliminate much of the guesswork now involved in choosing cancer treatments, says Oliver Jonas, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and lead author of a paper describing the device in the April 22 online edition ofScience Translational Medicine.

“You can use it to test a patient for a range of available drugs, and pick the one that works best,” Jonas says.

The paper’s senior authors are Robert Langer, the David H. Koch Professor at MIT and a member of the Koch Institute, the Institute for Medical Engineering and Science, and the Department of Chemical Engineering; and Michael Cima, the David H. Koch Professor of Engineering at MIT and a member of the Koch Institute and the Department of Materials Science and Engineering.

Putting the lab in the patient

Most of the commonly used cancer drugs work by damaging DNA or otherwise interfering with cell function. Recently, scientists have also developed more targeted drugs designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.

In some cases, doctors extract tumor cells, grow them in a lab dish, and treat them with different drugs to see which ones are most effective. However, this process removes the cells from their natural environment, which can play an important role in how a tumor responds to drug treatment, Jonas says.

“The approach that we thought would be good to try is to essentially put the lab into the patient,” he says. “It’s safe and you can do all of your sensitivity testing in the native microenvironment.”

The device, made from a stiff, crystalline polymer, can be implanted in a patient’s tumor using a biopsy needle. After implantation, drugs seep 200 to 300 microns into the tumor, but do not overlap with each other. Any type of drug can go into the reservoir, and the researchers can formulate the drugs so that the doses that reach the cancer cells are similar to what they would receive if the drug were given by typical delivery methods such as intravenous injection.

After one day of drug exposure, the implant is removed, along with a small sample of the tumor tissue surrounding it, and the researchers analyze the drug effects by slicing up the tissue sample and staining it with antibodies that can detect markers of cell death or proliferation.

Ranking cancer drugs

To test the device, the researchers implanted it in mice that had been grafted with human prostate, breast, and melanoma tumors. These tumors are known to have varying sensitivity to different cancer drugs, and the MIT team’s results corresponded to those previously seen differences.

The researchers then tested the device with a type of breast cancer known as triple negative, which lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. This form of cancer is particularly aggressive, and none of the drugs used against it are targeted to a specific genetic marker.

Using the device, the researchers found that triple negative tumors responded differently to five of the drugs commonly used to treat them. The most effective was paclitaxel, followed by doxorubicin, cisplatin, gemcitabine, and lapatinib. They found the same results when delivering these drugs by intravenous injection, suggesting that the device is an accurate predictor of drug sensitivity.

In this study, the researchers compared single drugs to each other, but the device could also be used to test different drug combinations by putting two or three drugs into the same reservoir, Jonas says.

“This device could help us identify the best chemotherapy agents and combinations for every tumor prior to starting systemic administration of chemotherapy, as opposed to making choices based on population-based statistics. This has been a longstanding pursuit of the oncology community and an important step toward our goal of developing precision-based cancer therapy,” says Jose Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center and an author of the paper.

The researchers are now working on ways to make the device easier to read while it is still inside the patient, allowing them to get results faster. They are also planning to launch a clinical trial in breast cancer patients next year.

“This is a stunning advance in the approach to treating complex cancers,” says Henry Brem, a professor of neurosurgery and oncology at Johns Hopkins School of Medicine who was not involved in the research. “This work is transformative in that it now opens the doors to truly personalized medicine with the right drug or drug combination being utilized for each tumor.”

Another possible application for this device is to guide the development and testing of new cancer drugs. Researchers could create several different variants of a promising compound and test them all at once in a small trial of human patients, allowing them to choose the best one to carry on to a larger clinical trial.

How to identify drugs that work best for each patient

Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy.

More than 100 drugs have been approved to treat cancer, but predicting which ones will help a particular patient is an inexact science at best.

A new device developed at MIT may change that. The implantable device, about the size of the grain of rice, can carry small doses of up to 30 different drugs. After implanting it in a tumor and letting the drugs diffuse into the tissue, researchers can measure how effectively each one kills the patient’s cancer cells.

Such a device could eliminate much of the guesswork now involved in choosing cancer treatments, says Oliver Jonas, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and lead author of a paper describing the device in the April 22 online edition ofScience Translational Medicine.

“You can use it to test a patient for a range of available drugs, and pick the one that works best,” Jonas says.

The paper’s senior authors are Robert Langer, the David H. Koch Professor at MIT and a member of the Koch Institute, the Institute for Medical Engineering and Science, and the Department of Chemical Engineering; and Michael Cima, the David H. Koch Professor of Engineering at MIT and a member of the Koch Institute and the Department of Materials Science and Engineering.

Putting the lab in the patient

Most of the commonly used cancer drugs work by damaging DNA or otherwise interfering with cell function. Recently, scientists have also developed more targeted drugs designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.

In some cases, doctors extract tumor cells, grow them in a lab dish, and treat them with different drugs to see which ones are most effective. However, this process removes the cells from their natural environment, which can play an important role in how a tumor responds to drug treatment, Jonas says.

“The approach that we thought would be good to try is to essentially put the lab into the patient,” he says. “It’s safe and you can do all of your sensitivity testing in the native microenvironment.”

The device, made from a stiff, crystalline polymer, can be implanted in a patient’s tumor using a biopsy needle. After implantation, drugs seep 200 to 300 microns into the tumor, but do not overlap with each other. Any type of drug can go into the reservoir, and the researchers can formulate the drugs so that the doses that reach the cancer cells are similar to what they would receive if the drug were given by typical delivery methods such as intravenous injection.

After one day of drug exposure, the implant is removed, along with a small sample of the tumor tissue surrounding it, and the researchers analyze the drug effects by slicing up the tissue sample and staining it with antibodies that can detect markers of cell death or proliferation.

Ranking cancer drugs

To test the device, the researchers implanted it in mice that had been grafted with human prostate, breast, and melanoma tumors. These tumors are known to have varying sensitivity to different cancer drugs, and the MIT team’s results corresponded to those previously seen differences.

The researchers then tested the device with a type of breast cancer known as triple negative, which lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. This form of cancer is particularly aggressive, and none of the drugs used against it are targeted to a specific genetic marker.

Using the device, the researchers found that triple negative tumors responded differently to five of the drugs commonly used to treat them. The most effective was paclitaxel, followed by doxorubicin, cisplatin, gemcitabine, and lapatinib. They found the same results when delivering these drugs by intravenous injection, suggesting that the device is an accurate predictor of drug sensitivity.

In this study, the researchers compared single drugs to each other, but the device could also be used to test different drug combinations by putting two or three drugs into the same reservoir, Jonas says.

“This device could help us identify the best chemotherapy agents and combinations for every tumor prior to starting systemic administration of chemotherapy, as opposed to making choices based on population-based statistics. This has been a longstanding pursuit of the oncology community and an important step toward our goal of developing precision-based cancer therapy,” says Jose Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center and an author of the paper.

The researchers are now working on ways to make the device easier to read while it is still inside the patient, allowing them to get results faster. They are also planning to launch a clinical trial in breast cancer patients next year.

“This is a stunning advance in the approach to treating complex cancers,” says Henry Brem, a professor of neurosurgery and oncology at Johns Hopkins School of Medicine who was not involved in the research. “This work is transformative in that it now opens the doors to truly personalized medicine with the right drug or drug combination being utilized for each tumor.”

Another possible application for this device is to guide the development and testing of new cancer drugs. Researchers could create several different variants of a promising compound and test them all at once in a small trial of human patients, allowing them to choose the best one to carry on to a larger clinical trial.

SELFAA is ready to come in 2026